Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) recently announced that the Korean Patent Office has granted it a new patent for DNA Polymerase IIIC inhibitors. While the headline suggests a positive development in the company's intellectual property portfolio, a deeper analysis reveals several critical factors that investors should consider. This patent grant is part of Acurx's ongoing efforts to enhance its competitive position in the pharmaceutical market, particularly in the development of novel antibiotics. However, it is essential to contextualize this announcement against the company's recent performance and market conditions.

In the past month, Acurx has faced significant volatility in its stock price, including a notable 108% rally just weeks prior to this patent announcement, followed by a pullback attributed to overbought signals. The stock's performance has been erratic, with a recent report indicating a staggering increase in short interest of 1,712.4% as of March 13, 2026, reaching 1,045,893 shares. This surge in short interest raises questions about market sentiment and investor confidence in Acurx's future prospects. The recent patent grant may have been anticipated by the market, and while it adds value to the company's intellectual property, it does not necessarily translate into immediate financial benefits or operational advancements.

Financially, Acurx reported a net loss of $1.6 million for the fourth quarter of 2025, which is an improvement from previous losses, and ended the year with $7.6 million in cash, a significant increase from $3.7 million at the end of 2024. This improvement reflects enhanced financial stability, but it also highlights the ongoing challenge of funding its operations and development programs. Given the company's market capitalization of $10.7 million, the cash balance provides a runway for approximately five months at the current burn rate. Investors should be cautious, as the company may need to raise additional capital to support its ongoing research and development efforts, particularly as it seeks to advance its pipeline of antibiotic candidates.

In terms of valuation, Acurx's current market cap places it within the micro-cap tier, which typically includes companies with market capitalizations between $5 million and $50 million. Direct peers in this space include companies such as Acurx Pharmaceuticals, which is focused on antibiotic development. However, identifying comparable firms that match Acurx's specific focus on DNA Polymerase IIIC inhibitors and fall within a similar market cap range is challenging. The lack of robust peer comparisons makes it difficult to assess whether Acurx's valuation is attractive relative to its competitors.

The execution track record of Acurx Pharmaceuticals raises additional concerns. The company has previously missed milestones and faced delays in its development timelines. The recent patent grant does not change the fact that Acurx has struggled to deliver on its promises consistently. Moreover, the significant increase in short interest suggests that many investors are betting against the company's future performance, which could indicate a lack of confidence in management's ability to execute its strategy effectively.

In conclusion, while the patent grant from the Korean Patent Office may appear to be a positive development for Acurx Pharmaceuticals, it is essential to consider the broader context of the company's financial health, market sentiment, and execution history. The announcement does not fundamentally alter the company's trajectory, and the risks associated with its funding and operational execution remain significant. Therefore, this announcement should be classified as moderate in its impact, with the headline sentiment not fully warranted by the underlying realities. Investors should approach Acurx with caution, given the potential for further volatility and the need for additional capital to support its ongoing development efforts.

Key insights

• ●Patent grant may not translate to immediate financial benefits.
• ●Short interest surged 1,712.4%, indicating bearish sentiment.
• ●Company's cash balance provides limited runway for operations.

Disagree with this article?